The DOI matches its Crossref record.
Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology
Open accessAbstract
Reperfusion therapy in ST-segment elevation myocardial infarction (STEMI) is the most important component of treatment, as it strongly influences short- and long-term patient outcome. The main objective of healthcare providers should be to achieve at least 75% of reperfusion therapy applied to patients suffering from STEMI in a timely manner, and preferably within the first 3 h after onset of symptoms. Establishing networks of reperfusion at regional and national level, implying close collaboration between all the actors involved in reperfusion therapy, namely hospitals, departments of cardiology, PCI centres, emergency medical systems (EMS), (para)medically staffed ambulances, private cardiologists, primary care physicians, etc., is a key issue. All forms of reperfusion, depending on local facilities, need to be available to patients. Protocols must be written and agreed for the strategy of reperfusion to be applied within a network. Early diagnosis of STEMI is essential and is best achieved by rapid ECG recording and interpretation at first medical contact, wherever this contact takes place (hospital or ambulance). Tele-transmission of ECG for immediate interpretation by experienced cardiologists is an alternative. Primary PCI is the preferred reperfusion option if it can be performed by experienced staff within 90 min after first medical contact. Thrombolytic treatment, administered if possible in the pre-hospital setting, is a valid option if PCI cannot be performed in a timely manner, particularly within the first 3 h following onset of symptoms. Thrombolysis is not the end of the reperfusion therapy. Rescue PCI must be performed in the case of thrombolysis failure. Next-day PCI after successful thrombolysis has been proven efficacious. Quality control is important for monitoring the efficacy of networks of reperfusion. All elements that influence time to reperfusion must be taken into account, particularly transfer delays, in-hospital delays, and door-to-balloon or door-to-needle times. The rate of reperfusion achieved must also be taken into consideration. Professional organizations such as the European Society of Cardiology (ESC) have the responsibility to impart this message to the cardiology community, and inform politicians and health authorities about the best possible strategy to achieve reperfusion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Authors/Task Force Members, Van de Werf, F., Bax, J., Betriu, A., Blomstrom-Lundqvist, C., Crea, F., Falk, V., Filippatos, G., Fox, K., Huber, K., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn416 · Cited by 2,310
Self-citationCardiovascular Disease and Diabetes: Policies for Better Health and Quality of Care
OECD (2015) · OECD Health Policy Studies · doi:10.1787/9789264233010-en · Cited by 1,359
Schmitt, J., Duray, G., Gersh, B. J., & Hohnloser, S. H. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehn579 · Cited by 611
Mandelzweig, L. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl196 · Cited by 603
Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease
Lai, R. C., Chen, T. S., & Lim, S. K. (2011) · Regenerative Medicine · doi:10.2217/rme.11.35 · Cited by 553
Metadata
- Authors
- Bassand, J.-P., Danchin, N., Filippatos, G., Gitt, A., Hamm, C., Silber, S., Tubaro, M., & Weidinger, F.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-11-25
- Volume
- 26
- Issue
- 24
- Pages
- 2733-2741
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2135227162
- Cited by
- 164
- References
- 0
- FWCI
- 11.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. https://app.cochat.ai/papers/10.1093/eurheartj/ehi673
- The paper
- Bassand, J.-P., Danchin, N., Filippatos, G., Gitt, A., Hamm, C., Silber, S., Tubaro, M., & Weidinger, F. (2005). Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. European Heart Journal. https://doi.org/10.1093/eurheartj/ehi673
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.